Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ENLV Stock Summary
Top 10 Correlated ETFs
ENLV
In the News

Enlivex to Present at the 2023 Jefferies Healthcare Conference
Nes-Ziona, Israel, June 06, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will present a corporate update at the 2023 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York, NY. The presentation will take place on June 9, 2022, at 11:30 AM Eastern Time. A webcast of the presentation will be available at https://wsw.com/webcast/jeff281/enlv/1860430, and will be archived for 90 days.

Enlivex to Present at the 4th Macrophage-Directed Therapies Summit
Nes-Ziona, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the 4th Macrophage-directed Therapies Summit, which is taking place in Boston, Massachusetts from October 4-6, 2022.

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech
Enlivex Therapeutics: The early results for Allocetra for sepsis (in humans) and solid tumors (in mice) look incredible. The share offering from 2021 shows a willingness to protect existing shareholders.

Enlivex to Present at the 2022 Jefferies Healthcare Conference
Nes-Ziona, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis and solid tumors, today announced that company management will present a corporate update at the 2022 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York, NY. The presentation will take place on June 9, 2022, at 1:00 PM Eastern Time. A webcast of the presentation will be available at https://wsw.com/webcast/jeff240/enlv/1853925 , and will be archived for 90 days.

Enlivex Therapeutics Stock (ENLV): Why The Price Increased Today
The stock price of Enlivex Therapeutics Ltd (NASDAQ: ENLV) increased by over 4% during intraday trading today. This is why it happened.

Enlivex CSO Prof. Dror Mevorach Publishes Foundational Paper on the Pfizer–BioNTech COVID-19 Vaccine in The New England Journal of Medicine
Publication follows the Israeli Ministry of Health's appointment of Prof. Mevorach as the lead investigator of a team evaluating side effects of COVID-19 vaccines

Enlivex to Present at Reuters Events' Cell & Gene Therapy USA 2021
Nes-Ziona, Israel, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the Reuters Events' Cell & Gene Therapy USA 2021 event, which is taking place virtually on September 28 and 29, 2021.

Enlivex Therapeutics (ENLV) Sees Hammer Chart Pattern: Time to Buy?
Enlivex Therapeutics (ENLV) has been struggling lately, but the selling pressure may be coming to an end soon.

Enlivex (ENLV) Begins Phase IIb COVID-19 Study on Cell Therapy
Enlivex (ENLV) doses the first patient in a phase IIb study evaluating its cell therapy, Allocetra, in severe and critical COVID-19 patients with acute respiratory distress syndrome.

Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS
ENLV Financial details
ENLV Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0.17 | 0 | 0 | |
Net income per share | -1.21 | -1.17 | -1.05 | -0.54 | -2.31 | |
Operating cash flow per share | -0.9 | -0.81 | -0.84 | -0.98 | -1.3 | |
Free cash flow per share | -1.03 | -0.84 | -0.91 | -1.07 | -1.74 | |
Cash per share | 2.79 | 1.39 | 2.71 | 4.71 | 2.62 | |
Book value per share | 2.77 | 1.3 | 2.69 | 4.76 | 3.09 | |
Tangible book value per share | 2.77 | 1.26 | 2.69 | 4.76 | 3.09 | |
Share holders equity per share | 2.77 | 1.3 | 2.69 | 4.76 | 3.09 | |
Interest debt per share | 0 | 0.01 | 0.02 | 0.03 | 0.55 | |
Market cap | 21.72M | 72.57M | 111.02M | 111.62M | 72.48M | |
Enterprise value | 11.99M | 68.74M | 105.55M | 101.04M | 29.5M | |
P/E ratio | -5.12 | -7.15 | -8.01 | -11.57 | -1.71 | |
Price to sales ratio | 0 | 0 | 48.76 | 0 | 0 | |
POCF ratio | -6.87 | -10.31 | -10.09 | -6.36 | -3.03 | |
PFCF ratio | -6 | -10.03 | -9.23 | -5.82 | -2.26 | |
P/B Ratio | 2.24 | 6.43 | 3.13 | 1.31 | 1.28 | |
PTB ratio | 2.24 | 6.43 | 3.13 | 1.31 | 1.28 | |
EV to sales | 0 | 0 | 46.35 | 0 | 0 | |
Enterprise value over EBITDA | -1.97 | -9.27 | -14.58 | -4.25 | -1.56 | |
EV to operating cash flow | -3.79 | -9.76 | -9.59 | -5.76 | -1.23 | |
EV to free cash flow | -3.31 | -9.5 | -8.78 | -5.27 | -0.92 | |
Earnings yield | -0.2 | -0.14 | -0.12 | -0.09 | -0.59 | |
Free cash flow yield | -0.17 | -0.1 | -0.11 | -0.17 | -0.44 | |
Debt to equity | 0 | 0.01 | 0.01 | 0.01 | 0.09 | |
Debt to assets | 0 | 0.01 | 0.01 | 0.01 | 0.07 | |
Net debt to EBITDA | 1.6 | 0.52 | 0.76 | 0.45 | 2.27 | |
Current ratio | 9.09 | 2.75 | 8.72 | 18.32 | 7.92 | |
Interest coverage | 0 | 0 | 0 | 0 | -4.9 | |
Income quality | 0.75 | 0.75 | 0.93 | 1.21 | 0.77 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 1.58 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 2.67 | 0 | 0 | |
Intangibles to total assets | 0 | 0.02 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.15 | 0.03 | 0.09 | 0.09 | 0.34 | |
Capex to revenue | 0 | 0 | -0.45 | 0 | 0 | |
Capex to depreciation | -3.81 | -0.94 | -3.56 | -2.98 | -10.45 | |
Stock based compensation to revenue | 0 | 0 | 0.29 | 0 | 0 | |
Graham number | 8.67 | 5.87 | 7.99 | 7.61 | 12.66 | |
ROIC | -0.68 | -0.81 | -0.32 | -0.15 | -0.56 | |
Return on tangible assets | -0.38 | -0.59 | -0.34 | -0.1 | -0.63 | |
Graham Net | 2.45 | 0.87 | 1.22 | 3.9 | 2.09 | |
Working capital | 9.15M | 10.44M | 33.75M | 81.72M | 45.72M | |
Tangible asset value | 9.71M | 10.87M | 35.49M | 85.04M | 56.84M | |
Net current asset value | 8.95M | 10.14M | 33.25M | 76.34M | 41.53M | |
Invested capital | 0 | 0.01 | 0.01 | 0.01 | 0.09 | |
Average receivables | 120.5K | 1.31M | 1.78M | 1.68M | 1.42M | |
Average payables | 96K | 244.5K | 389.5K | 670.5K | 1.41M | |
Average inventory | 0 | 0 | -15.6M | -21.7M | -5.51M | |
Days sales outstanding | 0 | 0 | 186.59 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 1.96 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.44 | -0.9 | -0.39 | -0.11 | -0.75 | |
Capex per share | -0.13 | -0.02 | -0.08 | -0.09 | -0.44 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.76 | -0.31 | -0.36 | -0.41 | -0.37 | |
Operating cash flow per share | -0.5 | -0.36 | -0.26 | -0.31 | -0.38 | |
Free cash flow per share | -0.69 | -0.42 | -0.4 | -0.32 | -0.38 | |
Cash per share | 3.4 | 2.1 | 2.62 | 1.94 | 1.56 | |
Book value per share | 3.73 | 3.44 | 3.09 | 2.73 | 2.39 | |
Tangible book value per share | 3.73 | 3.44 | 3.09 | 2.73 | 2.39 | |
Share holders equity per share | 3.73 | 3.44 | 3.09 | 2.73 | 2.39 | |
Interest debt per share | 0.25 | 0.29 | 0.23 | 0.28 | 0.24 | |
Market cap | 83.06M | 78.17M | 72.48M | 67.4M | 48.7M | |
Enterprise value | 63.53M | 44.87M | 29.5M | 58.94M | 49.61M | |
P/E ratio | -1.49 | -3.38 | -2.77 | -2.2 | -1.79 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -8.96 | -11.86 | -15.04 | -11.65 | -6.93 | |
PFCF ratio | -6.55 | -10.04 | -9.8 | -11.34 | -6.9 | |
P/B Ratio | 1.21 | 1.24 | 1.28 | 1.33 | 1.1 | |
PTB ratio | 1.21 | 1.24 | 1.28 | 1.33 | 1.1 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -11.16 | -8.18 | -3.87 | -8.97 | -7.71 | |
EV to operating cash flow | -6.85 | -6.81 | -6.12 | -10.19 | -7.06 | |
EV to free cash flow | -5.01 | -5.77 | -3.99 | -9.91 | -7.03 | |
Earnings yield | -0.17 | -0.07 | -0.09 | -0.11 | -0.14 | |
Free cash flow yield | -0.15 | -0.1 | -0.1 | -0.09 | -0.14 | |
Debt to equity | 0.01 | 0.08 | 0.09 | 0.09 | 0.1 | |
Debt to assets | 0.01 | 0.07 | 0.07 | 0.08 | 0.08 | |
Net debt to EBITDA | 3.43 | 6.07 | 5.64 | 1.29 | -0.14 | |
Current ratio | 15.44 | 13.08 | 7.92 | 6.89 | 6.17 | |
Interest coverage | -1.45 | -101.38 | 11.96 | -15.59 | 0 | |
Income quality | 0.94 | 1.15 | 0.67 | 0.8 | 1.03 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.37 | 0.18 | 0.54 | 0.03 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -19.31 | -6.2 | -11.68 | -0.78 | -0.18 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 7.98 | 4.94 | 4.97 | 5.04 | 4.45 | |
ROIC | -0.12 | -0.08 | -0.11 | -0.12 | -0.13 | |
Return on tangible assets | -0.18 | -0.08 | -0.1 | -0.13 | -0.13 | |
Graham Net | 3.02 | 2.18 | 2.09 | 1.5 | 1.17 | |
Working capital | 60.84M | 54.7M | 45.72M | 32.13M | 25.79M | |
Tangible asset value | 68.49M | 63.27M | 56.84M | 50.57M | 44.34M | |
Net current asset value | 56.2M | 50.09M | 41.53M | 28.13M | 22.09M | |
Invested capital | 0.01 | 0.08 | 0.09 | 0.09 | 0.1 | |
Average receivables | 1.82M | 1.96M | 1.06M | 1.13M | 1.74M | |
Average payables | 1.01M | 861.5K | 1.5M | 1.72M | 1.52M | |
Average inventory | 0 | 9.55M | 10.14M | 588.5K | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.2 | -0.09 | -0.11 | -0.15 | -0.15 | |
Capex per share | -0.18 | -0.06 | -0.14 | -0.01 | 0 |
ENLV Frequently Asked Questions
What is Enlivex Therapeutics Ltd. stock symbol ?
Enlivex Therapeutics Ltd. is a IL stock and trading under the symbol ENLV
Is Enlivex Therapeutics Ltd. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $15. The lowest prediction is $15 and the highest is $15
What is ENLV stock prediction ?
What is Enlivex Therapeutics Ltd. stock quote today ?
Enlivex Therapeutics Ltd. stock price is $1.56 today.
Is Enlivex Therapeutics Ltd. stock public?
Yes, Enlivex Therapeutics Ltd. is a publicly traded company.